Phathom Pharmaceuticals PHAT
- Market cap
- $480.8M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.7×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $274.9M
- +87% on a year ago
- Net margin
- −30.2%
- Free cash flow yield
- −4.4%
Phathom Pharmaceuticals trades at 1.7× sales. Its trailing earnings are negative, so it has no PE. Revenue was $274.9M over the last twelve months, up 87% on a year earlier with a −30% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $682K | $1.9M | $7.3M | $16.4M | $29.7M+4250% | $28.5M+1392% | $39.5M+439% | $49.5M+203% | $57.6M+94% | $58.3M+104% | $74.3M+88% | $84.7M+71% | |
| Cost of revenue | $167K | $426K | $1.4M | $2.4M | $3.8M+2184% | $3.7M+774% | $5M+266% | $6.2M+163% | $7.6M+101% | $12M+222% | $15.1M+200% | $18.4M+197% |
| Gross profit | $515K | $1.5M | $5.9M | $14M | $25.8M+4919% | $24.8M+1569% | $34.5M+479% | $43.3M+210% | $49.9M+93% | $46.3M+87% | $59.2M+72% | $66.4M+53% |
| R&D | $13.4M−16% | $9.4M−18% | $7.4M−42% | $8.7M−29% | $8.6M−36% | $9.2M−3% | $9.1M+23% | $7M−19% | $7.5M−13% | $7.8M−15% | $7.8M−14% | $8.7M+24% |
| SG&A | $57M+86% | $62M+233% | $75.9M+301% | $76.1M+225% | $76.7M+35% | $94.5M+52% | $85.3M+12% | $51.6M−32% | $48.4M−37% | $54M−43% | $55.3M−35% | $57.7M+12% |
| −$69.9M+50% | −$70M+133% | −$77.3M+144% | −$70.8M+99% | −$59.4M−15% | −$78.9M+13% | −$59.9M−23% | −$15.3M−78% | −$5.9M−90% | −$15.5M−80% | −$4M−93% | −$85K−99% | |
| Interest expense | $13M+36% | $17.2M+86% | $17.8M+85% | $18.5M+83% | $18.6M+43% | $18.1M+5% | $17.5M−1% | $16.1M−13% | $16.4M−12% | $15.8M−13% | $15.1M−14% | $15.4M−5% |
| Net income | −$79.6M+45% | −$82.9M+119% | −$91.4M+123% | −$85.6M+98% | −$74.5M−6% | −$94.3M+14% | −$75.8M−17% | −$30M−65% | −$21.1M−72% | −$30.4M−68% | −$17.6M−77% | −$13.9M−54% |
| −$1.39+5% | −$1.42+60% | −$1.56+86% | −$1.32+74% | −$1.05−25% | −$1.31−8% | −$1.05−33% | −$0.41−69% | −$0.29−72% | −$0.37−72% | −$0.21−80% | −$0.16−61% | |
| 57.3M+39% | 58.4M+38% | 58.6M+21% | 64.6M+14% | 71M+24% | 72M+23% | 72.5M+24% | 73.4M+14% | 73.8M+4% | 82.1M+14% | 83.7M+16% | 84.9M+16% |
EPS, diluted: 5 periods, Q4 FY21 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 5 periods, Q4 FY21 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Phathom Pharmaceuticals' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| PHATPhathom Pharmaceuticals | $480.8M | n/m | n/a | 1.7× | +87% | −30.2% | |
| ARVNArvinas | $491.7M | 47.0× | 50.5× | 1.6× | −15% | 2.9% | |
| PBYIPuma Biotechnology | $525.5M | 19.6× | 12.3× | 2.3× | −3% | 11.6% | |
| CRMDCorMedix | $420.1M | 2.5× | 4.0× | 0.9× | +281% | 40.5% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.8× | 1.5× | +26% | 33.4% | |
| ZVRAZevra Therapeutics | $599.8M | 10.9× | 12.2× | 4.4× | +119% | 42.8% | |
| COLLCollegium Pharmaceutical | $770.9M | 19.1× | 19.1× | 1.0× | +14% | 5.9% | |
| ABUSArbutus Biopharma | $791.4M | 5.1× | 5.6× | 4.4× | n/m | 84.2% | |
| NATRNatures Sunshine Products | $211.5M | 11.9× | 20.2× | 0.4× | +7% | 3.7% | |
| AMPHAmphastar Pharmaceuticals | $1.1B | 15.9× | 20.5× | 1.6× | +1% | 10.8% | |
| OMEROmeros | $1.3B | 11.7× | 11.7× | n/m | n/m | n/m | |
| Peer median | $585.8M | 11.8× | 13.5× | 1.6× | +11% | 11.6% |
More on Phathom Pharmaceuticals
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .